In what scenarios (if ever) would you check peripheral blood flow cytometry in a patient with known multiple myeloma to evaluate for circulating plasma cells (CPCs) in the absence of an abnormal smear?

The question alludes to the fact that there is substantial data now on the prognostic implications of circulating plasma cells at diagnosis. Jelinek et al., PMID 36315921 showed that 2%+ CPCs are associated with a plasma cell leukemia-like phenotype. Much lower levels of CPCs were also associated wi...